IMC Chicago’s AstraZeneca AZN Stock Holding History

IMC Chicago’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,753	Closed	-$3.64M	–	4062
2025 Q3	$3.18M	Sell	20,753 -1,196	-5%	-$181K	﹤0.01%	1912
2025 Q2	$3.07M	Buy	+21,949	New	+$3.08M	﹤0.01%	1720
2024 Q2	–	Sell	-5,041	Closed	-$759K	–	2620
2024 Q1	$683K	Buy	+5,041	New	+$668K	﹤0.01%	1905
2021 Q1	–	Sell	-28,293	Closed	-$2.84M	–	1037
2020 Q4	$2.83M	Buy	+28,293	New	+$3M	﹤0.01%	666

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

IMC Chicago's AZN Position: Q4 2025 in Review

IMC Chicago sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 20,753 shares — an estimated $3.64M sold.

IMC Chicago first reported a position in AZN in Q4 2020 and held it in 4 quarters. The position peaked at $3.18M in Q3 2025. 1,405 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

IMC Chicago reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
IMC Chicago sold 20,753 AstraZeneca shares in Q4 2025, an estimated $3.64M.
IMC Chicago first reported a position in AstraZeneca in Q4 2020 and held it in 4 quarters.
IMC Chicago's AstraZeneca position peaked at $3.18M in Q3 2025.
1,405 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on IMC Chicago's 13F filing for Q4 2025, filed 29 Jan 2026.